Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

The European Union could not say when a joint statement on tariffs with the United States would be ready, nor when the White House would issue an executive or ...

Schuyler County is to receive a settlement from a New Jersey pharmaceutical company and its affiliates after the county argued it contributed to the ongoing opioid ...

Burr is leading the Coalition for Smarter Regulation of Nicotine's efforts to convince, if not prod, the Food and Drug Administration into increasing efforts to remove unregulated Chinese vaping produ ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Novartis ADR NVS had its Relative Strength (RS) Rating upgraded from 66 to 71 Tuesday — a welcome improvement, but still short of the 80 or better score you prefer to see. Please watch the video at ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

Royalty Pharma Plc (NASDAQ:RPRX) is one of the top most undervalued biotech stocks to buy now. In a report released on August ...

Sandoz will oversee commercialization of the product across the European Union (excluding Germany), Switzerland, Norway, ...